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Abstract
Isolation of viral pathogens from clinical and/or animal samples has traditionally relied on
either cell cultures or laboratory animal model systems. However, virus viability is notori-
ously susceptible to adverse conditions that may include inappropriate procedures for sam-
ple collection, storage temperature, support media and transportation. Using our recently
described ISA method, we have developed a novel procedure to isolate infectious single-
stranded positive-sense RNA viruses from clinical or animal samples. This approach, that
we have now called "ISA-lation", exploits the capacity of viral cDNA subgenomic fragments
to re-assemble and produce infectious viral RNA in susceptible cells. Here, it was success-
fully used to rescue enterovirus, Chikungunya and Tick-borne encephalitis viruses from a
variety of inactivated animal and human samples. ISA-lation represents an effective option
to rescue infectious virus from clinical and/or animal samples that may have deteriorated
during the collection and storage period, but also potentially overcomes logistic and admin-
istrative difficulties generated when complying with current health and safety and biosecu-
rity guidelines associated with shipment of infectious viral material.
Introduction
Isolation of viruses using cell culture or laboratory animals has, for many years, been the “gold
standard” for human and veterinarian clinical virology laboratories [1–2] and also for environ-
mental virology studies [3]. Despite the recent development of sensitive and specific molecular
detection methods, in particular in routine virological diagnostic laboratories [4–6], virus isola-
tion remains essential as a non-oriented diagnostic technique and it also provides a reference
infectious virus that can be used for phenotypic and genotypic characterisation as well as a vari-
ety of applied sciences including antiviral drug-screening assays, structural analysis and studies
of the fundamental basis of virus pathogenesis [7].
Conventionally, the isolation of viral pathogens requires infectious virus to be present in the
sample. Unfortunately, viability can readily be compromised due to intrinsic fragility of the
virus, inappropriate sample collection, unsuitable transportation and/or storage conditions, or
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when the sample is inactivated prior to shipment or laboratory manipulation, using methods
compatible with subsequent analysis techniques (e.g. heat treatment or the addition of chaotro-
pic reagents for serological or molecular analyses).
Reverse genetics potentially enables the recovery of infectious viruses directly from nucleic
acids encoding the viral genomes. The most commonly used “infectious clone” system utilises
an engineered DNA copy of the viral genome stably incorporated into a vector and amplified
in an appropriate host (most commonly, a plasmid vector in a bacterial host). The use of
reverse genetics to recover infectious virus is a particularly attractive option when investigating
a large range of field samples previously considered to be intractable for isolation of infectious
virus. Indeed, reverse genetics has been used to recover infectious simian immunodeficiency
virus and separately adeno-associated virus, neither of which could be recovered directly from
clinical samples using conventional tissue culture methods [8–10]. Nevertheless, despite recent
improvements in molecular techniques, the protocols remain difficult and laborious [11–12]
and are not suitable for routine use in diagnostic laboratories.
We have recently developed a novel, highly sensitive and technically simple method which
facilitates recovery of infectious single-stranded positive-sense RNA viruses from nucleic acids.
The method, based on the generation of infectious subgenomic amplicons (ISA) involves (i)
PCR amplification of the complete viral genome as overlapping non-infectious DNA frag-
ments; (ii) flanking the first and last fragments respectively in 5’ and 3’ with the human cyto-
megalovirus promoter (pCMV) and the hepatitis delta ribozyme followed by the simian
virus 40 polyadenylation signal (HDR/SV40pA); and (iii) transfecting amplicons directly in
susceptible cells [13].
Here, we demonstrate that the ISA method is a convenient tool for isolating single-stranded
positive-sense RNA viruses from samples that contain inactivated virus. This new procedure,
termed "ISA-lation", has now been successfully tested with a variety of single-stranded posi-
tive-sense RNA viruses. Based on the results presented herein, the ISA-lation protocol has the
potential to rescue infectious viruses from a wide variety of human, animal and environmental
field samples that would otherwise have produced negative results under conventional condi-
tions for virus isolation.
Materials and Methods
General strategy
The ISA-lation procedure comprises the following steps (a detailed protocol of each step fol-
lows this paragraph) (Fig 1):
• Nucleic acid extraction from (inactivated) samples
• Preparation of genomic overlapping PCR fragments
• Cell transfection of amplicons
• Detection of viral production
Clinical samples used in the current study (Table 1)
Human samples: Because (i) biological analysis (virus detection and isolation) were prescribed
by physician, (ii) only leftovers were used,(iii) the results obtained in this study had no impact
on patient’s management and (iv) oral non-opposition was obtained during hospital admission
of the patients, specific consent from patients and ethics committee approval were not required
for this study (according to national regulations: “Interprétation des réglementations relatives
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aux études liées aux DMDIV nécessitant la collecte d’échantillons d’origine humaine; Agence
Francaise de Sécurite Sanitaire des Produits de Santé; 30 July 2013”).
One pharyngeal swab and one stool sample collected during an outbreak in Marseille,
France, in 2013, as previously described [14], and testing positive for enterovirus using a
one-step RT-PCR method [15]. The enteroviruses were subsequently genotyped as Echovirus
Fig 1. Schematic representation of the ISA-lation method used to recover infectious viruses from
clinical samples. Viral RNA directly extracted from clinical samples was used to amplify by RT-PCR the
entire viral genome in 3 overlapping cDNA fragments. The human cytomegalovirus promoter (pCMV) and the
hepatitis delta ribozyme followed by the simian virus 40 polyadenylation signal (HDR/SV40pA), were then
added respectively at the 5’ and 3’ termini of the first and last fragment as described in the Results/Discussion
section. Transfection of the 3 final overlapping DNA fragments into permissive cells enabled the isolation and
recovery of infectious viruses after 3 to 9 days.
doi:10.1371/journal.pone.0138703.g001
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30 (E-30; Human Enterovirus B; genus Picornavirus; i.e. a non-enveloped virus with a single
stranded RNA genome of positive polarity, polyadenylated at its 3' end) by direct partial
sequencing of the VP1 gene [16].
One human serum testing positive, using a one-step RT-PCR method [17], for the presence
of chikungunya virus (CHIKV; genus Alphavirus; i.e. an enveloped virus with a single stranded
RNA genome of positive polarity, polyadenylated at its 3' end), collected during the epidemic
that is currently affecting the Caribbean [18].
Animal sample: A brain suspension filtrate collected from a five-week-old C57Bl/6J female
mouse inoculated intraperitoneally with 2.106 TCID50 of the strain Oshima 5–10 of tick-borne
encephalitis virus (TBEV; genus Flavivirus; an enveloped virus with a single stranded RNA
genome of positive polarity, not polyadenylated at its 3' end) and sacrificed 7 days later as
previously described [19]. Animal experiments were approved by the Ethics Committee
“Marseille-C2EA-14” (ref. #2504) and performed in compliance with French and European
regulations (directive 210/63/EU).
Sample inactivation and extraction of nucleic acids
Samples were inactivated using one volume of AVL buffer (Qiagen, containing guanidinium
salts [20]) for one volume of sample. Extraction of nucleic acid was performed using the EZ1
advanced XL machine (Qiagen) with the EZ1 Virus Mini Kit v2.0 (Qiagen).
Preparation of genomic overlapping amplicons
Three overlapping amplicons were produced from the RNA extract of each clinical sample.
RT-PCR assays were performed using the Superscript III One-Step RT-PCR Platinum TaqHifi
kit (Life Technologies). The mixture (final volume: 50 μL) contained 25 μL of Reaction Mix,
2 μL of nucleic acid extract, 100 nM of each primer, 1 μL of Enzyme Mix and 20 μL of Nucle-
ase-Free Water. Primers were designed from the full-length sequence of the virus when avail-
able (TBEV, CHIKV) or from the alignment of sequences from related viruses retrieved from
GenBank (E-30) (Tables A and B in S1 File).
The amplicons obtained were as follows (positions according to full-length genomic
sequence). TBEV_1: 1–4970, TBEV_2: 3866–8026, TBEV_3: 7851–11100; E-30_1: 6–2287, E-
30_2: 2166–5404, E-30_3: 5232–7441; CHIKV_1: 1–3635, CHIKV_2: 3486–7112, CHIKV_3:
6998–11296. Of note, whilst the complete TBEV viral genome was amplified at this stage, this
Table 1. Summary of the different viruses isolated in this study with the ISA-lation method. Nature of the sample used for isolation, cell lines used for
transfection and passage, relative quantification of the amount of viral RNA in the sample and after two passages by real-time RT-PCR, infectious titres in
supernatant media after two passages by TCID50 assay and presence or absence of cytopathic effect (CPE).
Virus Nature of the
specimen
Viral RNA in the
original
specimen (copy/
mL)
Cell line used
for transfection
Cell line used
during
passages
Viral RNA in
supernatant medium
after two passages
(copy/mL)
TCID50/mL in
supernatant medium
after two passages
Observation
of CPE
TBEV Filtrate from
mouse brain
suspension
2.85 105 HEK-293 BHK-21 1.87 107 3.16 106 Yes
CHIKV Human serum 5.72 105 HEK-293 HEK-293 2.01 107 3.72 106 Yes
E-30 Human
pharyngeal
swab
2.15 103 HEK-293 MRC-5 7.05 106 4.17 106 Yes
Human stools 1.15 106 HEK-293 MRC-5 5.34 107 3.16 106 Yes
doi:10.1371/journal.pone.0138703.t001
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was not the case for the first 6 nucleotides of E-30 virus, and the final 740 and 39 nucleotides at
the 3’ end of the CHIKV and E-30 genomes, respectively.
Addition of the CMV promoter (pCMV) at the 5’ end of the first cDNA
fragment
For each virus defined above, the pCMV was amplified by PCR from a previously available
plasmid [13] using a forward specific primer and a reverse primer extended with the first
~twenty nucleotides (nt) of the viral genome (TBEV: 20 nt; CHIKV: 25 nt; E-30: 24 nt). This
tagged pCMV and the first cDNA fragments were then merged by fusion PCR to obtain the
final first DNA genomic fragments (Table B in S1 File) (Fig 1). All PCR assays were per-
formed using the Platinum PCR SuperMix High Fidelity kit (Life Technologies). The mixture
(final volume, 50 μl) consisted of 45 μl SuperMix, 2 μL DNA template at 1 ng/μL and 200 nM
of each primer. The final amplicons were obtained as follows (positions according to full-length
genomic sequence). TBEV_1: 5’ terminus of the pCMV-4054, CHIKV_1: 5’ terminus of the
pCMV-3607.
Addition of the hepatitis delta ribozyme followed by the simian virus 40
polyadenylation signal (HDR/SV40pA) at the 3’ end of the last cDNA
fragment
In the case of TBEV (no 3’-polyadenylated genome), the HDR/SV40pA was amplified by PCR
from a previously available plasmid [13] using a forward primer extended with the last 21
nucleotides of the viral genome. This tagged HDR/SV40pA and the third cDNA fragment were
then merged by fusion PCR (Table B in S1 File) (Fig 1).
For RNA viruses with a 3’-polyadenylated genome (i.e., CHIKV and E-30), the 740
(CHIKV) or 39 (E-30) final nucleotides of the viral genome, the polyA tail and the HDR/
SV40pA were synthesized de novo (Genscript) (Notes A and B in S1 File) and then merged by
fusion PCR with the pre-amplified final third of the viral genome (Table B in S1 File) (Fig 1).
The final amplicons were obtained as follows (positions according to full-length genomic
sequence). TBEV_3: 7935–3’ terminus of the HDR/SV40pA, CHIKV_3: 7023–3’ terminus of
the HDR/SV40pA.
Cell preparation and transfection
All cells were cultured at 37°C with 5% CO2 using reagents from Life Technologies. Baby Ham-
ster Kidney (BHK-21) cells: Minimal Essential Medium with 7% heat-inactivated foetal bovine
serum and 1% Penicillin/Streptomycin (PS); Human Embryonic Kidney 293 (HEK-293): same
medium supplemented with 1% of non-essential amino acids; Human foetal lung fibroblast
(MRC-5): Basal Medium Eagle with 10% FBS and 1% PS.
For a given virus, 1 μg of an equimolar mix of the 3 subgenomic amplicons was mixed with
12 μl of Lipofectamine 2000 (Life Technologies) in 600 μl of Opti-MEM medium (Life Tech-
nologies) and added to a 12.5 cm2 culture flask containing sub-confluent HEK 293 cells in
1 mL of medium without antibiotics. After a 4 hour incubation period, the supernatant
medium was removed, cells were washed twice (HBSS; Life Technologies) and 3 mL of fresh
medium were added.
Detection of viral production
The supernatant medium was harvested when gross cytopathic effect (CPE) was observed (4–8
days depending on the cell type and the rate of virus replication), clarified by centrifugation,
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and then sequentially passaged twice using the same cell type for the CHIKV, BHK-21 cells for
TBEV and MRC-5 cells for E-30 virus. These sequential passages were performed to ensure the
complete elimination of the original DNA used during the transfection step. Sequential pas-
sages were performed by inoculating 333 μL of clarified infectious supernatant medium onto
cells in a 12.5 cm2 culture flask containing 666 μL of medium. After incubation for 2 hours,
cells were washed twice (HBSS) and 3 mL of fresh medium was added. The supernatant
medium was harvested after 2–6 days, clarified by centrifugation, aliquoted and stored at
-80°C. Clarified supernatant media (virus stocks) were used to performquantification of viral
RNA, TCID50 assay, and whole-genome sequencing.
Real time PCR and RT-PCR assays. Nucleic acids were extracted from supernatant
media using the EZ1 mini virus 2.0 kit and the EZ1 advanced XL machine (both from Qiagen)
according to the manufacturer's instructions.
To assess the production of infectious viruses and to ensure that positive detection was not
the result of DNA contamination, viral RNA and DNA sequences were semi-quantified using
qRT-PCR (GoTaq1 qPCR Master Mix kit, Promega) and qPCR (Takyon No Rox Probe Mas-
terMix kit, Eurogentec) assays under standard amplification conditions at a 60°C hybridisation
temperature.
For qRT-PCR tests, the mixture (final volume: 20 μL) contained 10 μL of Master Mix 2X
Reaction Buffer, 0.5 μM of each primer, 0.3 μL of probe, 0.5 μL of GoSCRIPT RT Mix, 0.87 μL
of Nuclease-Free Water and 7.5 μL of extracted nucleic acids. For qPCR tests, the mixture
(final volume: 25 μL) contained 12.5 μL of TakyonTMMasterMix, 0.5 μM of each primer,
0.3 μL of probe, 3.55 μL of Nuclease-Free Water and 7.5 μL of extracted nucleic acids (Table C
in S1 File).
The quantity of viral RNA (number of genome copies per mL) was calculated by compari-
son with calibrated standard curves produced from serial dilutions of nucleic acids.
Tissue Culture Infectious Dose 50 (TCID50) assay. For each determination, a 96-well
plate culture containing either 20,000 human adrenal carcinoma (SW13) cells (for TBEV),
MRC-5 cells (for E-30) or African green monkey kidney (Vero) cells (for CHIKV) in 100 μL of
medium per well was inoculated with 50 μL of serial 10-fold dilutions of clarified infectious
supernatant medium. Each row included 6 wells of the same dilution and two negative con-
trols. The plates were incubated for 7 days and read for absence or presence of CPE in each
well. The determination of the TCID50/mL was performed using the method of Reed and
Muench [21].
Sequence analysis of full-length genomes. Next-Generation Sequencing (NGS) of com-
plete genomes was performed using the Ion PGM Sequencer [22] (Life Technologies) and anal-
yses were conducted with the CLC Genomics Workbench 6 software. RNA was extracted from
supernatant medium using the EZ1 mini virus 2.0 kit and the EZ1 advanced XL machine (both
from Qiagen) according to the manufacturer's instructions. Complete viral genomes were
amplified in three or four fragments using specific sets of primers with the Superscript III One-
Step RT-PCR Platinum TaqHifi kit (Life Technologies) as described above. Amplified DNA
was analysed using the Ion PGM Sequencer according to the manufacturer's instructions. The
read sequences obtained were trimmed, first using quality score, then by removing the primers
used to amplify the complete genome by RT-PCR and finally at the 5’ and 3’ termini by system-
atically removing 6 nt. Only reads with a length greater than 29 nt were used and mapped for
comparison to thesequences of the corresponding viruses: CHIKV H20235/STMARTIN/2013
strain (available through the European Virus Archive website under reference no. 1540), the
TBEV Oshima 5–10 strain (GenBank accession number AB062063) or the E-30 1-MRS2013
strain (GenBank accession number KF920598). Mutation frequencies (proportion of viral
genomes with the mutation) for each position were calculated simply as the number of reads
"ISA-Lation" of RNA Viruses from Clinical/Animal Samples
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with a mutation compared to the reference divided by the total number of reads at that site. All
reads are available in NCBI Sequence Read Archive; BioProject PRJNA291127; accession num-
ber SRP062989.
For viruses (CHIKV and TBEV) for which the sequence of the original virus contain in the
sample was known, the integrity of the sequenced genomes was considered as verified when
the nucleotides similarity was99.9%.
For viruses (E-30) for which the sequence of the original virus contain in the sample was
unknown, the integrity of the sequenced genomes was verified by aligning with the closest
complete genomes available in the database.
Results
We attempted to recover infectious single-stranded positive-sense RNA viruses from inacti-
vated biological specimens (pharyngeal swab, stools, serum and brain tissue) using a method
derived from the previously described ISA method [13]. For each specimen, the procedure was
designed to produce an equimolar mix of 3 overlapping DNA fragments covering the complete
viral genome with pCMV and HDR/SV40pA sequences at the 5'and 3' termini, respectively
(Fig 1), and to transfect HEK-293 cells with this preparation.
The amount of TBEV RNA in the brain suspension filtrate was 2.85 105 copies/mL. Follow-
ing transfection, a cytopathic effect (CPE) was observed at day 8. Supernatant medium was
subsequently sequentially passaged twice on BHK-21 cells. CPE was observed at each passage.
On completion of the second passage (P2), the quantities of viral RNA measured in the culture
supernatant medium were 1.87 107 copies/mL (i.e., higher than in the initial sample) and the
titre of infectious particles was 3.16 106 TCID50/mL (Table 1). NGS complete genomic
sequencing confirmed the integrity of the genome structure and the genetic similarity with the
TBEV Oshima 5–10 strain used for infecting mice (Tables D and E in S1 File).
The amount of CHIKV RNA in the original serum was 5.72 105 copies/mL. Following trans-
fection, CPE was observed at day 8. Supernatant medium was then sequentially passaged twice
on HEK-293 cells. CPE was observed at each passage. At passage two, the amounts of viral
RNA and infectious particles in the culture supernatant medium were respectively 2.01 107
copies/mL (i.e., higher than in the initial sample) and 3.72 106 TCID50/mL (Table 1). NGS
complete genomic sequencing confirmed the integrity of the genome structure and the genetic
similarity with CHIKV H20235/STMARTIN/2013 strain, isolated during the same epidemic
[18] (Tables D and E in S1 File).
The amount of E-30 RNA in the original samples was 2.15 103 copies/mL in the pharyngeal
swabs and 1.15 106 copy/mL in stools. CPE was observed at day 8 post transfection. Superna-
tant medium was sequentially passaged twice onto MRC-5 cells, with renewed CPE. The
amounts of viral RNA and infectious particles in the P2 supernatant media deriving from the
pharyngeal swab were 7.05 106 copies/mL (i.e., higher than in the initial sample) and 4.17 104
TCID50/mL. They were 5.34 10
7 copies/mL (i.e., higher than in the initial sample) and 3.16 104
TCID50/mL in supernatant media derived from stools (Table 1). NGS complete genomic
sequencing confirmed the integrity of the genome structure and the genetic similarity with the
E-30 1-MRS2013 strain isolated during the same outbreak [14] (Tables D and E in S1 File).
Discussion
We have developed a technically simple but scientifically sophisticated procedure designated
“ISA-lation” which facilitates the rescue of infectious single-stranded positive-sense RNA
viruses from clinical samples in which, for a variety of reasons, virus infectivity has been lost
but genomic RNA has retained sufficient fidelity to enable authentic RT-PCR amplification.
"ISA-Lation" of RNA Viruses from Clinical/Animal Samples
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Here, we have validated this rescue procedure for viruses belonging to three different families
which harbour different characteristics (enveloped; non-enveloped; polyadenylated; non-poly-
adenylated), starting from a variety of inactivated clinical samples (serum, brain tissue, pharyn-
geal swabs and stools).
This procedure possesses several important advantages over previous molecular identifica-
tion methods. Moreover, ISA-lation overcomes problems associated with health, safety and
security as follows. Firstly, ISA-lation provides a method of rescuing viruses from clinical sam-
ples or cell cultures that no longer contain detectable infectious viruses resulting from inappro-
priate sample collection, transportation and/or inappropriate storage conditions. Secondly,
and importantly, national and international health, safety and security regulations applicable
to development, exchange and transportation of infectious materials, impose increasing costs
and preparation times and highly significant restriction on the shipment of infectious agents.
Exploitation of the ISA-lation protocol provides biological tools for fundamental research,
virus discovery and rescue in a diagnostic context and incidentally circumvent most, if not all,
of the problems associated with safe shipment of high level pathogens. Thus, clinical samples
suspected of containing pathogenic viruses that prove to be unretrievable by conventional
virus isolation procedures are now potentially amenable to the ISA-lation rescue process via
technically simple procedures and at relatively low cost. Furthermore, by deliberately inactivat-
ing samples directly after collection, this procedure effectively reduces the perceived risk of
infection and also preserves the viral RNA for molecular diagnosis and subsequent virus recov-
ery using the ISA-lation procedure. An additional advantage is that field sampling procedures
are significantly simplified in the absence of the constraints associated with the need for pre-
serving virus infectivity. Finally, the ISA-lation procedure also enables recovery of a particular
virus in the presence of interfering agents such as multi-resistant bacteria, fungi or even other
viruses that may replicate faster than the targeted virus population. Furthermore, in contrast
with some reverse genetics protocols that include cloning steps, ISA-lation, which is based on
production of cDNA fragments using PCR, could conserve the genetic diversity of the viral
population present in the original specimen [23].
Thus, the ISA-lation procedure for rescuing infectious viruses from clinical/animalsamples
will complement other molecular technologies that include real time RT-PCR which can be
used to detect and quantify viral genomes in targeted samples, Next-Generation Sequencing
methods that enable genomic characterisation directly from the sample, and therefore facilitate
the design of ISA primers [18], and de novo DNA synthesis technologies, which could be alter-
natively used to generate cDNA fragments [13].
In conclusion, the procedure that we have termed ISA-lation represents a specific, sensitive,
novel and technically simple procedure for rescuing positive-stranded RNA genomes as infec-
tious viruses from clinical and/or animalsamples that would otherwise fail to yield infectious
virus if conventional virus isolation procedures were used. For example, many samples tested
in diagnostic laboratories may have deteriorated due to poor collection and storage methods.
Alternatively, the infectious virus may be undetectable because it is present below the threshold
level for detection by conventional methods, as for example in cases of persistent infection. In
other cases, the sample may have been tested and found positive by molecular biological meth-
ods but failed to yield infectious virus using cell culture isolation methods. Using the much
more sensitive ISA-lation procedure, the only essential requirement is that the sample must
contain amplifiable full-length genomic RNA. In addition, the ISA-lation procedure has a
major practical application which potentially overcomes logistic and administrative difficulties
generated when complying with current health and safety and biosecurity guidelines. This
applies when working with hazardous virus pathogens. Using ISA-lation procedures, a hazard-
ous positive-stranded RNA virus can be safely transported as separate DNA fragments from
"ISA-Lation" of RNA Viruses from Clinical/Animal Samples
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one compliant laboratory to another without the need for expensive safety containment proce-
dures. Clearly, the next step is to develop the ISA-lation method for other viruses.
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